CLINICAL TRIAL BREAST CANCER Clinical Title: A Phase II Clinical Trial to Ameliorate Symptoms of Cognitive Impairment in Women Treated with Chemotherapy for Breast Cancer: The COGNUTRIN Trial Description: This is an innovative strategy to address the patient cognitive problem. This is a real problem and one of the first attempts to deal with cognitive impairment syndrome. This is a non-invasive approach that can be applied very quickly. Very important study. Clinical Description: One of the most common side effects of chemotheraphy for breast cancer is cognitive impairment, commonly described as chemobrain. This occurs in approximately 30-75% of patients and may last from 6 months to 10 years. Interventions that demonstrated promise in the aging population have not been evaluated to ameliorate chemobrain in cancer patients treated with chemotherapy. The current study tests the hypothesis is that supplementation with a combination of a standard formulation of anthocyanins and n-3 fatty acids (COGNUTRIN) work synergistically to reduce oxidative stress loads of inflammatory cytokines that reduce cognitive functioning. demandcurestoday.org/cancer-research/phase-ii-cognitive-impairment-in-women-with-breast-cancer-the-cognutrin-trial
Posted on: Sat, 21 Sep 2013 23:28:24 +0000
Trending Topics
Recently Viewed Topics
© 2015